Micofenolato De Mofetilo Stada

Mycophenolate Mofetil, the active ingredient in Micofenolato De Mofetilo Stada, is an antimetabolite immunosuppressant presented as an oral formulation for oral use. It is employed to prevent acute organ transplant rejection and to treat lupus nephritis in appropriate patient populations.

GNH USA supplies Micofenolato De Mofetilo Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.

Mycophenolate Mofetil is used in immunosuppressive regimens targeting organ transplantation and autoimmune kidney disease.

- Acute organ transplant rejection: helps prevent rejection episodes after solid‑organ transplantation. - Kidney transplant: reduces the risk of graft loss and improves long‑term graft survival. - Lupus nephritis: diminishes renal inflammation and slows disease progression in systemic lupus erythematosus patients.

Mycophenolate Mofetil may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: frequent loose stools, sometimes leading to dehydration. - Headache: transient cranial discomfort. - Abdominal pain: cramping or discomfort in the stomach area. - Vomiting: occasional emesis, especially after dose initiation. - Infections: increased susceptibility to bacterial, viral, or fungal infections.

Serious or Rare Side Effects: - Leukopenia: significant reduction in white blood cell count. - Anemia: decreased red blood cell levels causing fatigue. - Severe infections: opportunistic infections such as Pneumocystis jirovecii pneumonia. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Malignancy risk: potential increased risk of lymphoproliferative disorders. - Progressive multifocal leukoencephalopathy (PML): rare but life‑threatening brain infection.

Patients receiving Mycophenolate Mofetil should be monitored closely for safety and efficacy.

- Blood counts: monitor complete blood count regularly to detect leukopenia or anemia. - Renal function: assess serum creatinine and glomerular filtration rate, especially in transplant recipients. - Pregnancy: avoid use during pregnancy; drug is classified as Category D. - Contraception: ensure effective contraception for both male and female patients of reproductive potential. - Drug interactions: review concomitant medications that may affect mycophenolate exposure. - Storage: Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

Mycophenolate Mofetil interacts with several agents that may alter its efficacy or safety.

Major Interactions (Avoid): - Azathioprine: additive bone‑marrow suppression. - Cyclosporine or tacrolimus: increased risk of nephrotoxicity and infections. - Cholestyramine or colestipol: reduces oral absorption of mycophenolic acid.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: may potentiate renal impairment. - Warfarin: possible alteration of anticoagulant effect. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): increased risk of gastrointestinal irritation. - Live vaccines: heightened risk of vaccine‑derived infection.